Veraxa Biotech is trading 6.57% down at $0.96; the reason for the decline remains unclear. - No company-specific catalyst for November 3 was confirmed in the search. The investor-relations site lists October 13 as its latest release. - A human-relevant testing update dates to October 30, but neither item establishes a cause. - Biotech was higher in the supplied sector context, opposite to the stock’s move, and does not explain the drop.